These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34581415)

  • 1. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152.
    Yadav PD; Sahay RR; Sapkal G; Nyayanit D; Shete AM; Deshpande G; Patil DY; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34581415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.
    Yadav PD; Sapkal GN; Ella R; Sahay RR; Nyayanit DA; Patil DY; Deshpande G; Shete AM; Gupta N; Mohan VK; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34230972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
    Sapkal GN; Yadav PD; Ella R; Deshpande GR; Sahay RR; Gupta N; Vadrevu KM; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772577
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.
    Lassaunière R; Polacek C; Fonager J; Bennedbæk M; Boding L; Rasmussen M; Fomsgaard A
    Euro Surveill; 2021 Dec; 26(49):. PubMed ID: 34886943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    Sahay RR; Patil DY; Sapkal GN; Deshpande GR; Shete AM; Nyayanit DA; Kumar S; Yadav PD
    J Infect; 2022 Apr; 84(4):e36-e38. PubMed ID: 35192896
    [No Abstract]   [Full Text] [Related]  

  • 8. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals.
    Sapkal GN; Yadav PD; Sahay RR; Deshpande G; Gupta N; Nyayanit DA; Patil DY; Shete AM; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34343316
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
    Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
    Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine.
    Sapkal G; Yadav PD; Ella R; Abraham P; Patil DY; Gupta N; Panda S; Mohan VK; Bhargava B
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34002240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
    Boccuto A; Dragoni F; Bergna A; Ventura CD; Giammarino F; Saladini F; Pezzati L; Zehender G; Zazzi M; Vicenti I; Lai A
    J Infect; 2022 Jan; 84(1):94-118. PubMed ID: 34371077
    [No Abstract]   [Full Text] [Related]  

  • 12. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.
    Wilhelm A; Toptan T; Pallas C; Wolf T; Goetsch U; Gottschalk R; Vehreschild MJGT; Ciesek S; Widera M
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
    Saade C; Gonzalez C; Bal A; Valette M; Saker K; Lina B; Josset L; Trabaud MA; Thiery G; Botelho-Nevers E; Paul S; Verhoeven P; Bourlet T; Pillet S; Morfin F; Trouillet-Assant S; Pozzetto B; On Behalf Of Covid-Ser Study Group
    Emerg Microbes Infect; 2021 Dec; 10(1):1499-1502. PubMed ID: 34176436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.